Loading clinical trials...
Loading clinical trials...
Phase Ib/IIa, Open-label, Multicenter, Dose Escalation, and Dose Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Solid Tumors
Conditions
Interventions
HCB101
Trastuzumab
+17 more
Locations
1
China
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China
Start Date
March 13, 2025
Primary Completion Date
January 1, 2028
Completion Date
January 1, 2029
Last Updated
February 4, 2026
NCT07186842
NCT03514368
NCT07371663
NCT07161310
NCT07114627
NCT06666270
Lead Sponsor
FBD Biologics Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions